On Friday, Following U.S. Stocks were among the “Top Gainers”:Ebix (NASDAQ:EBIX), Investment Technology Group (NYSE:ITG), FXCM (NYSE:FXCM),Repligen (NASDAQ:RGEN)

Ebix Inc (NASDAQ:EBIX), with shares inclined 15.38%, closed at $29.55 hitting new 52-week high of $30.20.

Investment Technology Group (NYSE:ITG), with shares jumped 14.90%, settled at $27.91, hitting new 52-week high of $28.40.

FXCM Inc (NYSE:FXCM), with shares climbed 20.00%, and closed at $2.58.

Repligen Corporation (NASDAQ:RGEN), surged 16.74%, and closed at $31.31, hitting new 52-week high of $32.19.

Latest NEWS regarding these Stocks are depicted underneath:

Ebix Inc. (NASDAQ:EBIX)

Ebix Inc. (EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial and healthcare industries, stated results for the fiscal fourth quarter and full year ended December 31, 2014.

Ebix delivered the following results for the fourth quarter and full year of 2014:

Proceed: Total Q4 2014 proceed was $60.6 million, an raise of 19% on a year-over-year basis, as contrast to Q4 2013 proceed of $50.8 million and an raise of $9.8 million over Q3 2014 proceeds of $50.8 million.

On a year-over-year basis, Ebix’s Q4 2014 proceed was affected negatively by about $1.1 million due to the strengthening of the US dollar as against the currencies in certain of the foreign jurisdictions in which the Corporation conducts operations. Also, on a constant currency basis, the Corporation’s Q4 2014 Proceeds would have been $1.2 million higher as contrast to Q3 2014.

For the full fiscal year of 2014, the Corporation stated proceed of $214.3 million, an raise of 5% from the preceding year proceed of $204.7 million. On a year-over-year basis, Ebix’s full year 2014 proceed was affected negatively by about $3.2 million due to the strengthening of the US dollar as against the currencies in certain of the foreign jurisdictions in which the Corporation conducts operations.

Earnings per Share:

Q4 2014 diluted earnings per share raised 14% year-over-year to $0.45, as contrast to $0.40 in the fourth quarter of 2013. For purposes of the Q4 2014 EPS calculation, there was an average of 36.8 million diluted shares outstanding during the quarter contrast to 38.5 million during the same period in 2013.

For the full year of 2014, diluted earnings per share raised 9% year-over-year to $1.67 from $1.53 in 2013. For purposes of the EPS calculation, there was an average of about 38.0 million diluted shares outstanding during the year 2014 as contrast to an average of 38.6 million diluted shares outstanding in 2013.

Operating Cash:

Cash generated from operations for the fiscal fourth quarter was $20.1 million, up 4% year-over-year, and up 106% as contrast to $9.7 million in Q3 of 2014. For the full year, operating cash flow totaled $58.5 million in 2014, up 3% year-over-year as contrast to $57.1 million in 2013.

Operating Margins:

Operating margins for Q4 2014 were consistent with Q4 2013 at 35%. The operating margins for fiscal year 2014 were, also, consistent with the preceding year remaining at 37%.

Net Revenue:

Q4 2014 net revenue was $16.5 million, a 9% raise on a year-over-year basis, as contrast to Q4 2013 net revenue of $15.2 million. During fiscal year 2014, net revenue raised $4.3 million or 7%, to $63.6 million contrast to $59.3 million during 2013.

Channel Proceeds:

The Exchange channel continued to be the largest channel for Ebix accounting for 79% of the Corporation’s 2014 Proceeds.

The quarter-over-quarter Exchange proceed raise is primarily due to the attainment of Oakstone, stronger growth from existing product lines, partially offset by the considerable strengthening of the US dollar as contrast to the Australian dollar and the Brazilian real. The quarter-over-quarter RCS proceed raise is primarily due to the attainments of Vertex and i3.

A leading international supplier of On-Demand software and E-commerce services to the insurance, financial and healthcare industries, Ebix, Inc., (EBIX) provides end-to-end solutions ranging from infrastructure exchanges, carrier systems, agency systems and risk compliance solutions to custom software development for all entities involved in the insurance industry.

Investment Technology Group Inc. (NYSE:ITG)

Investment Technology Group Inc. (ITG), an independent execution and research broker, recently offered stockholders with an update on the Corporation’s review of its capital allocation policies, declaring that its Board of Directors has approved a plan to significantly raise the Corporation’s share repurchase levels and to form a board-level committee to continue reviewing ITG’s overall capital allocation framework. ITG also confirmed that it has received notice from Philadelphia Financial Administration of San Francisco, LLC and Voce Capital Administration LLC announcing their intent to nominate three candidates to stand for election to the ITG Board of Directors at the Corporation’s 2015 Annual Meeting of Stockholders. ITG stockholders are not required to take any action at this time.

ITG is an independent execution and research broker that partners with global portfolio managers and traders to provide unique data-driven insights throughout the investment process. From investment decision through settlement, ITG assists clients understand market trends, improve performance, mitigate risk and navigate increasingly complex markets.

FXCM Inc. (NYSE:FXCM)

FXCM Inc. (FXCM), released its February 2015 Operating Metrics.

Fourth Quarter 2014 Highlights:

• S. GAAP proceeds of $134.7 million, up 19% as compared to the same period in 2013 and up 16% from the third quarter 2014
• S. GAAP net revenue attributable to FXCM Inc. of $15.8 million or $0.35 per fully diluted share as compared to $0.08 per fully diluted share for the same period in 2013 and $0.05 per fully diluted share in the third quarter 2014
• Adjusted EBITDA of $40.8 million, up 53% as compared to the same period in 2013 and up 43% from the third quarter 2014
• Net revenue on an adjusted basis of $16.1 million or $0.20 per fully exchanged, fully diluted share up 120% and 100% respectively as compared to the same period in 2013 and as compared to $8.4 million or $0.11 per share in the third quarter 2014
• Adding back tax-effected amortization and stock based compensation, Net revenue on an adjusted basis would have been $0.27 per diluted share for the fourth quarter

Subsequent to Year-End:

• On January 15th, 2015, FXCM customers generated negative equity balances owed to the company of about $276 million due to the unprecedented volatility in the Swiss Franc
• On January 16th, 2015, the company reached a $300 million financing transaction with Leucadia National Corporation
• FXCM has since repaid $12 million of the facility and is in the process of disposing of non-core assets to further repay a portion of the debt.

February 2015 Operating Metrics Highlights:

• Retail customer trading volume of $267 billion, 12% lower than February 2014
• Institutional customer trading volume of $162 billion, unchanged from February 2014

FXCM Inc., through its auxiliaries, provides online foreign exchange (FX) trading and related services to retail and institutional customers worldwide.

Repligen Corporation (NASDAQ:RGEN)

Repligen Corporation (RGEN), stated financial results for the fourth quarter and year ended December 31, 2014. Below are the Corporation’s performance highlights for these periods.

Business Highlights of 2014:

• In June, the company attained the business of Refine Technology and its market-leading ATF System used in the fermentation step of bio-manufacturing. During the fourth quarter, the ATF business was merged into their Waltham, Massachusetts site as The company accomplished the construction of their state-of-the-art ATF manufacturing area that became operational during the first quarter of 2015. ATF System sales over the seven months were $6.8 million, which was well ahead of their initial expectations and met the 2014 contingent consideration milestone defined in the Refine Asset Purchase Contract. Based on achieving the 2014 milestone and the raised probability of achieving the 2015 sales milestone, the company accrued $2.0 million in contingent consideration in the fourth quarter.
• In March, The company formally launched their OPUS(R) 45 cm diameter chromatography columns which have the largest capacity presently accessible on the market. Adoption of OPUS 45 was very strong, contributing to OPUS growth of over 100% for the full year. OPUS columns are delivered pre-packed to customers with their choice of media used to purify monoclonal antibodies and other biologic drugs.
• The company invested substantially in their commercial infrastructure in 2014, enabling us to more effectively sell their proprietary products directly to end users worldwide and support the launch of new products in 2015.
• The company strengthened their administration team with the hiring of Tony J. Hunt as Chief Operating Officer and Jon K. Snodgres as Chief Financial Officer. Mr. Hunt will transition into the role of President and Chief Executive Officer following Mr. Herlihy’s retirement as President and Chief Executive Officer effective as of the Corporation’s Annual Meeting of Stockholders on May 21, 2015.

Repligen Corporation, a life sciences corporation, develops, manufactures, and markets consumable bio-processing products for use in the production of monoclonal antibodies and other biologic drugs.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable stheirces, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.